Antibacterial Resistance Leadership Group (ARLG) begins clinical trial of phage therapy for cystic fibrosis
The trial is evaluating whether the bacteriophage, or “phage,” therapy is safe and able to reduce the amount of bacteria in the lungs of volunteers
The Antibacterial Resistance Leadership Group (ARLG) has begun a clinical trial of phage therapy for cystic fibrosis in adults who carry Pseudomonas aeruginosa (P. aeruginosa) in their lungs, according to a statement from the National Institute of Health (NIH).
The trial is evaluating whether the bacteriophage, or